- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic polyconjugate (DPC) technology for safe and effective delivery of siRNA. The white paper may be found on the Arrowhead website at www.arrowheadresearch.com.
Safe and effective siRNA delivery has been a key challenge to the field of therapeutic RNAi. The DPC platform was developed over many years by scientists at Arrowhead's newly acquired Madison, Wisconsin research and development facility to overcome this challenge. The technology is a radical departure from the standard liposomal or lipid nanoparticle siRNA delivery systems used by the majority of RNAi therapeutics companies. It represents one of the most promising solutions to the delivery problem that has plagued the RNAi therapeutics field since its inception. The white paper traces the development of the DPC platform from initial work published in 2007, detailing the critical advances in chemistry and architecture that have occurred over the past four years and culminated in the demonstration of safe and effective delivery of siRNAs to hepatocytes and tumor cells in non-human primates.
"DPCs are elegant, customizable, and powerful new tools to solve the delivery challenge in RNAi and enable the creation of a large variety of new therapeutics," said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. "Studies in non-human primates have shown that DPCs are highly effective and have safety margins well beyond those currently achievable by other systems. Moreover, the modular nature of DPC technology and its ability to optimize individual components within the same polymer provide the potential to target all types of cells. This unparalleled delivery solution complements Arrowhead's portfolio of advanced siRNA delivery solutions, positioning the company as a partner of choice for large biotech and pharmaceutical companies interested in creating RNAi therapeutics."
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead is a leader in delivering small RNAs for gene silencing, and has programs in anti-obesity therapeutics and regenerative medicine.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email .
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
For more information, please click here
Investor Relations Contact:
Brandi Floberg or Kathy Price
The Piacente Group, Inc.
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers